Genmab A/S (NASDAQ: GMAB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 27.19 | EPS (ttm) | 1.27 | Insider Own | - | Shs Outstand | 613.94M | Perf Week | 7.14% |
| Market Cap | 21.20B | Forward P/E | 19.98 | EPS next Y | 1.73 | Insider Trans | - | Shs Float | 606.43M | Perf Month | 4.76% |
| Enterprise Value | 24.95B | PEG | 1.17 | EPS next Q | 0.35 | Inst Own | - | Short Float | 1.13% | Perf Quarter | 36.00% |
| Income | 788.00M | P/S | 5.13 | EPS this Y | -6.17% | Inst Trans | - | Short Ratio | 3.11 | Perf Half Y | 33.58% |
| Sales | 4.13B | P/B | 3.56 | EPS next Y | 45.04% | ROA | 6.30% | Short Interest | 6.83M | Perf YTD | 12.11% |
| Book/sh | 9.70 | P/C | 14.10 | EPS next 5Y | 23.27% | ROE | 13.58% | 52W High | 35.43 -2.54% | Perf Year | 22.27% |
| Cash/sh | 2.45 | P/FCF | 22.91 | EPS past 3/5Y | -42.87% -26.58% | ROIC | 9.91% | 52W Low | 23.62 46.19% | Perf 3Y | -6.52% |
| Dividend Est. | - | EV/EBITDA | 20.45 | Sales past 3/5Y | -36.45% -18.11% | Gross Margin | 39.92% | Volatility | 2.33% 2.02% | Perf 5Y | -23.01% |
| Dividend TTM | - | EV/Sales | 6.04 | EPS Y/Y TTM | -89.54% | Oper. Margin | 13.81% | ATR (14) | 0.80 | Perf 10Y | 119.24% |
| Dividend Ex-Date | - | Quick Ratio | 2.44 | Sales Y/Y TTM | -80.81% | Profit Margin | 8.17% | RSI (14) | 63.52 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.46 | EPS Q/Q | 0.00% | SMA20 | 2.92% | Beta | 0.82 | Target Price | 38.25 |
| Payout | 0.00% | Debt/Eq | 0.93 | Sales Q/Q | 24.86% | SMA50 | 10.29% | Rel Volume | 1.22 | Prev Close | 34.40 |
| Employees | 3,119 | LT Debt/Eq | 0.88 | Earnings | Nov 05 | SMA200 | 17.30% | Avg Volume | 2.22M | Price | 34.53 |
| IPO Date | Jun 01, 2009 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 51.66% 3.46% | Net Debt/EBITDA | 2.71 | Volume | 2,703,020 | Change | 0.38% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-22-26 | Reiterated | New Street | $43 | |
| Jul-22-26 | Upgrade | TD Cowen | Hold → Buy | |
| May-27-26 | Reiterated | Truist Financial | Buy | $48 → $40 |
| Apr-30-26 | Reiterated | HC Wainwright & Co. | Buy | $39 → $38 |
| Mar-26-26 | Initiated | Wolfe Research | Outperform | $32 |
| Feb-23-26 | Reiterated | Guggenheim | Buy | $43 → $40 |
| Feb-17-26 | Resumed | Jefferies | Buy | $42 |
| Jan-20-26 | Reiterated | HC Wainwright & Co. | Buy | $40 → $39 |
| Oct-06-25 | Reiterated | Truist Financial | Buy | $46 → $49 |
| Oct-02-25 | Reiterated | HC Wainwright & Co. | Buy | $50 → $40 |
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,131 | 3,723 | 21,526 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 288 | 309 | 985 | — | — | — | — | — | — | |
| Gross Profit | 3,843 | 3,414 | 20,541 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 727 | 602 | 3,790 | — | — | — | — | — | — | |
| Research and Development | 1,782 | 1,560 | 9,748 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 300 | — | — | — | — | — | — | |
| Operating Income | 1,334 | 1,251 | 6,703 | — | — | — | — | — | — | |
| Interest Expense | 269 | 61 | 120 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -159 | 15 | 2,581 | — | — | — | — | — | — | |
| Net Income Before Taxes | 906 | 1,205 | 9,164 | — | — | — | — | — | — | |
| Income Taxes | 118 | 241 | 1,320 | — | — | — | — | — | — | |
| Consolidated Net Income | 788 | 964 | 7,844 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 788 | 964 | 7,844 | — | — | — | — | — | — | |
| Net Income | 788 | 964 | 7,844 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.28 | 1.55 | 12.14 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.28 | 1.55 | 12.14 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.27 | 1.54 | 12.14 | — | — | — | — | — | — | |
| EBITDA | 1,220 | 1,337 | 9,697 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 27.19 | 20.00 | 1.72 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.12 | 5.15 | 0.63 | — | — | — | — | — | — | |
| Gross Margin | 93.03 | 91.70 | 95.42 | — | — | — | — | — | — | |
| Operating Margin | 32.29 | 33.60 | 31.14 | — | — | — | — | — | — | |
| Net Margin | 19.08 | 25.89 | 36.44 | — | — | — | — | — | — | |
| Shares Outstanding | 613 | 622 | 646 | — | — | — | — | — | — | |
| Market Capitalization | 21,167 | 19,158 | 13,482 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |